Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

HCW Biologics Inc

Healthcare US HCWB

1.63USD
0.00(0%)

Last update at 2026-06-05T20:23:00Z

Day Range

1.551.70
LowHigh

52 Week Range

0.912.32
LowHigh

Fundamentals

  • Previous Close 1.63
  • Market Cap41.98M
  • Volume704809
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-27.09716M
  • Revenue TTM3.93M
  • Revenue Per Share TTM0.11
  • Gross Profit TTM 4.10M
  • Diluted EPS TTM-0.76

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -14.90070M -12.86247M -5.80220M -7.29292M
Minority interest - - - -
Net income -14.72263M -12.35710M -5.77988M -7.22057M
Selling general administrative 8.33M 4.98M 2.44M 1.80M
Selling and marketing expenses - - - -
Gross profit 2.59M - 4.10M -
Reconciled depreciation 0.72M 0.54M 0.60M 0.42M
Ebit -15.07878M -13.36783M -5.82453M -7.36527M
Ebitda -14.77404M -12.82424M -5.22861M -6.94346M
Depreciation and amortization 0.30M 0.54M 0.60M 0.42M
Non operating income net other - - - -
Operating income -15.07878M -13.36783M -5.82453M -7.36527M
Other operating expenses 21.80M 13.37M 9.92M 7.37M
Interest expense 0.13M 0.51M 0.00000M 0.00000M
Tax provision - - - -
Interest income - 0.51M 0.02M 0.07M
Net interest income -0.12666M 0.51M 0.02M 0.07M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -0.17808M -0.50537M -0.02232M -0.07235M
Total revenue 6.72M 0.00000M 4.10M 0.00000M
Total operating expenses 17.67M 13.37M 9.92M 7.37M
Cost of revenue 4.14M - - -
Total other income expense net 0.18M 0.51M 0.02M 0.07M
Discontinued operations - - - -
Net income from continuing ops -15.20544M -12.86247M -5.80220M -7.29292M
Net income applicable to common shares -14.90070M -12.86247M -7.07388M -7.78253M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 28.51M 46.81M 53.51M 15.40M 10.07M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.27M 0.20M 1.44M 0.65M 0.24M
Total liab 15.05M 9.38M 2.32M 1.00M 1.07M
Total stockholder equity 13.46M 37.43M 51.19M 14.40M 9.00M
Deferred long term liab - - - - -
Other current liab 2.43M 1.73M 2.10M 0.85M 0.67M
Common stock 0.00360M 0.00359M 0.00358M 0.00048M 0.00047M
Capital stock 0.00360M 0.00359M 0.00358M 31.12M 18.68M
Retained earnings -70.53232M -45.53805M -30.63734M -16.71888M -9.67677M
Other liab - - - - -
Good will - - - - -
Other assets - 0.33M 0.39M 0.03M 0.03M
Cash 3.60M 22.33M 11.73M 8.46M 7.36M
Cash and equivalents - - - - -
Total current liabilities 8.75M 2.96M 2.32M 1.00M 1.07M
Current deferred revenue - - - - -
Net debt 2.86M -15.91646M -11.73068M -8.45583M -7.35583M
Short term debt 0.15M 6.41M - - -
Short long term debt - - - - -
Short long term debt total 6.45M 6.41M - - -
Other stockholder equity 83.99M 82.96M 81.83M - -
Property plant equipment - 10.80M 1.12M 1.62M 2.00M
Total current assets 6.40M 34.07M 40.48M 12.15M 8.03M
Long term investments 1.60M 1.60M 11.52M 1.60M 0.00000M
Net tangible assets - 37.43M 51.19M -16.71840M -9.67629M
Short term investments 0.00000M 9.74M 24.98M - -
Net receivables 1.54M 0.42M 0.13M 2.50M 0.00000M
Long term debt 6.30M 6.41M - - -
Inventory - 1.39M 2.20M 0.54M -
Accounts payable 6.17M 1.23M 0.22M 0.16M 0.39M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -53.51483M - -
Additional paid in capital - - - - -
Common stock total equity - 0.00359M - 0.00048M 0.00047M
Preferred stock total equity - - - - -
Retained earnings total equity - -45.53805M - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.06M 0.33M 0.39M 0.03M 0.03M
Deferred long term asset charges - - - - -
Non current assets total 22.11M 12.74M 13.03M 3.25M 2.04M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 24.98M -34.97165M -0.18668M -1.46009M
Change to liabilities 0.42M 1.89M -0.62865M 0.77M
Total cashflows from investing activities 14.71M -35.01891M -0.18668M -1.46009M
Net borrowings 6.45M 6.45M 0.56M 0.56M
Total cash from financing activities 6.27M 49.27M 11.72M 13.45M
Change to operating activities 2.35M -2.79942M -2.11826M -0.66222M
Net income -14.90070M -12.86247M -5.80220M -7.29292M
Change in cash 10.60M 3.27M 1.10M 5.22M
Begin period cash flow 11.73M 8.46M 7.36M 2.13M
End period cash flow 22.33M 11.73M 8.46M 7.36M
Total cash from operating activities -10.38611M -10.97572M -10.43133M -6.76517M
Issuance of capital stock 0.02M 56.03M 11.15M 13.45M
Depreciation 0.72M 0.54M 0.60M 0.42M
Other cashflows from investing activities - - - 0.00016M
Dividends paid - 2.82M - -
Change to inventory - - - -
Change to account receivables -0.28469M 2.37M -2.50000M -2.50000M
Sale purchase of stock -0.17477M - - -
Other cashflows from financing activities 6.26M -3.93797M 11.71M 13.39M
Change to netincome 1.31M -0.14050M 0.02M 0.00176M
Capital expenditures 10.28M 0.05M 0.19M 1.46M
Change receivables -0.28469M - - -
Cash flows other operating 2.36M - - -
Exchange rate changes - - - -
Cash and cash equivalents changes 10.60M - - -
Change in working capital 2.49M 1.46M -5.24691M 0.10M
Stock based compensation 1.12M 0.36M 0.02M 0.00176M
Other non cash items 0.19M 0.03M -9.43048M -
Free cash flow -20.66124M -11.02298M -10.61801M -8.22542M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
HCWB
HCW Biologics Inc		 - -% 1.63 - - 19.43 4.10 20.39 -2.4572
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

HCW Biologics Inc

2929 North Commerce Parkway, Miramar, FL, United States, 33025

Key Executives

Name Title Year Born
Dr. Hing C. Wong Ph.D. Founder, CEO, Director & Sec. 1954
Ms. Rebecca Byam CPA, M.B.A. Chief Financial Officer 1956
Dr. Peter Rhode Ph.D. Chief Scientific Officer & VP of Clinical Operations 1958
Ms. Nicole Valdivieso Esq. VP of Legal Affairs NA
Ms. Raquel Diaz M.S. Director of HR NA
Mr. Lee D. Flowers Sr. VP of Bus. Devel. 1946
Ms. Raquel Diaz M.S. Director of Human Resources NA
Dr. Hing C. Wong Ph.D. Founder, CEO, Director & Secretary 1954
Ms. Nicole Valdivieso Esq. Vice President of Legal Affairs NA
Mr. Lee D. Flowers Senior Vice President of Business Development 1946

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.